· BRIMOCHOL™ PF, a treatment for presbyopia, is an asset licensed from Tenpoint Therapeutics, Ltd.
HONG KONG, 6 November 2025 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that the Company has entered into a distribution and supply agreement with the leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals (“PT Ferron”), for the domestic commercialization of one of the Company’s core asset BRIMOCHOLTM PF, an innovative drug for the treatment of presbyopia, licensed from Tenpoint Therapeutics, Ltd (“Tenpoint Therapeutics”).
Under the terms of the agreement, Zhaoke grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the Product in Indonesia. The Company will receive an upfront payment and is eligible to receive additional milestone payments based on specific achievements.
In June 2025, Tenpoint Therapeutics, Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA accepted the New Drug Application (“NDA”) for the drug. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “I am excited to announce our second partnership with PT Ferron in just three months. This achievement underscores PT Ferron’s strong recognition of Zhaoke and our innovative therapy, BRIMOCHOL™ PF, for presbyopia. This new collaboration not only reinforces our relationship with PT Ferron but also enhances our presence in Indonesia, a crucial and most populous market in Southeast Asia. With hundreds of millions of people in the region, including those in Indonesia, affected by presbyopia, we are confident that this partnership will enable us to provide BRIMOCHOL™ PF to those who need it the most. Together with PT Ferron, we look forward to increasing access to this innovative treatment and improving vision health throughout the region.”
About BRIMOCHOLTM PF and BRIO-II Phase 3 Study
BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.
Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s[1] and becomes almost universal by age 50[2]. Presbyopia impacts billions of people globally[3] with approximately 600 million adults affected in China, South Korea and Southeast Asia[4]. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData[5]. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.
About PT Ferron Par Pharmaceuticals
PT Ferron Par Pharmaceuticals, a member of Dexa Group is a
fast-growing pharmaceutical company that started its operation in 2001.
PT Ferron Par Pharmaceuticals has demonstrated its global competitiveness by exporting products to the United Kingdom since 2008 especially Metformin SR tablets since 2011, Glucient SR tablets to the Netherlands since 2018, and Avamina SR tablets to Poland since 2019.
Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the New Drug Application (NDA) and has received a Prescription Drug User Fee Act (PDUFA) date from the U.S. Food and Drug Administration (FDA) of Jan. 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.
- End -
__________________________________________
[1] World report on vision. (2019). Retrieved 29 April, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2
[2] Polat, U., Schor, C., Tong, JL. et al. Training the brain to overcome the effect of aging on the human eye. Sci Rep 2, 278 (2012). https://doi.org/10.1038/srep00278
[3] Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012.
[4] Tenpoint Therapeutics data on file
[5] GlobalData’s Epidemiology Market Size Search extracted on 18 December 2024.
